Genetically engineered mouse models (GEMMs) of PDAC recapitulate human pancreatic cancer in a number of ways, including in their resistance to standard therapies.19 Thus, we used GEMMs to assess whether tumours with activation of the mTOR pathway would be exquisitely sensitive to mTOR inhibition. Here, MTOR is linked to pancreatic neoplasm.